Authors reply to letter to the editor by Dr Degens et al.

We thank Dr Degens et al. for their interesting comments. Our study aimed at evaluating the relationship between survival of patients receiving immune checkpoint inhibitors (ICPI, targeting PD-1 - PD-L1 pathway) and sarcopenia or cachexia in non-small cell lung cancer (NSCLC). took into account other known predictive factors ICPI efficiency, particularly tissue immunostaining score all patients. concluded that both negatively influenced outcome therapy. Letter to EditorLung CancerVol. 153PreviewWith great interest, we read paper entitled ‘Cachexia – as a determinant disease control rate inhibitors’ Lung Cancer. Treatment with (ICI), without chemotherapy, is currently standard medical care metastatic non small (NSCLC) [2]. However, not benefit. For optimal cost effective implementation this relatively new treatment, it important identify clinical characteristics biomarkers, which can predict ICI effectiveness. Full-Text PDF